Scientific information remains useful only when its source, methods, population and limitations stay attached to the reported result.

The trial tested one postoperative setting

A multicentre, randomized, double-blind, placebo-controlled proof-of-concept study enrolled 117 adults undergoing small or large bowel resection. It evaluated ipamorelin in the postoperative hospital setting, with the study registered as NCT00672074.

The protocol’s key efficacy endpoint was time from the first study treatment to tolerance of a standardized solid meal. Defining that endpoint before looking at the results is essential: it tells readers what the trial was principally designed to answer.

Evidence should become more specific as a claim becomes more consequential.

The key efficacy analysis did not show a significant difference

The publication reported median times to a first tolerated meal of 25.3 hours in the ipamorelin group and 32.6 hours in the placebo group. The reported comparison was not statistically significant (p=0.15), and the authors stated that key and secondary efficacy analyses did not show significant differences.

This is a valuable evidence record precisely because it is not a promotional outcome. It illustrates why a numerical difference, without the planned analysis and uncertainty, should not be converted into a claim of benefit.

The EternaGen reporting standard
  • Link to the original source.
  • Name the study design and population.
  • Report the observed endpoint factually.
  • Disclose important limitations.
  • Never convert trial reporting into a product recommendation.

A small proof-of-concept trial cannot settle the question

The authors described the study as small and noted its broad range of underlying conditions. A negative result in this protocol does not prove that every related hypothesis is false; it does mean this trial did not establish efficacy on its key or secondary analyses.

This record concerns an intravenous clinical trial in postoperative patients. It is not evidence for a research product, a different route or formulation, or any personal outcome. No human-use recommendation is made here.

Primary references

These sources were checked against the linked publisher, regulator or literature-index record on 21 July 2026.

  1. Beck et al. Prospective, randomized, controlled proof-of-concept study of ipamorelin for postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014. PMID 25331030.
  2. ClinicalTrials.gov. NCT00672074: Study of ipamorelin for postoperative ileus.
Educational content only. This article does not constitute medical advice, a therapeutic claim or a recommendation for human or veterinary use.